entertainment -WSS

entertainment

author：explore 2025-09-29 13:09:45 - browse：43

Drugmakers already bet big on mRNA for cancer. Now President Biden is going in, too? Anna Moneymaker/Getty Images

WASHINGTON — President Biden’s fledgling health agency, designed to accelerate under-funded research, just set its sights on one of the hottest areas of medicine — and one where the drug industry has a multibillion-dollar head start.

The White House announced Wednesday that the Advanced Research Projects Agency for Health would bankroll a $24 million project by Emory University to build messenger RNA platforms to target “cancer and other diseases,” investing in the technology behind the U.S.’s most commonly used vaccines for Covid-19.

The administration touted the news of CUREIT as the latest in Biden’s longtime mission to rein in cancer deaths, the Cancer Moonshot. But by using mRNA to treat cancer, ARPA-H is wading into a field that has advanced in fits and starts — and whose industry leaders have already spent multiples of the program’s entire budget into their own research. Moderna and BioNTech, massively profitable companies that have sold more than $80 billion worth of Covid-19 vaccines combined, have singled out oncology as the next big application for mRNA and invested accordingly.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： As H5N1 spreads in cows, experts warn against drinking raw milk

knowledge

hotspot

WSS

Ripples from Flovent's discontinuation is killing children with asthma

Inaction leaves children at risk from dangerous chemotherapy drug

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Update the Apgar Score to remove skin color

ALS treatment from Biogen, Ionis fails in study

Oak Street deal isn't the answer to health care's woes

hotspot

entertainment

hotspot

Supreme Court strikes down use of affirmative action

Medicare bonuses could stop drug shortages under Senate plan

What does generative AI mean for health care? We asked experts

FDA sets aggressive timeline for overhauling inspection procedures

State Dept. review finds Biden bears some blame for Afghanistan failures

Raw milk easy to obtain despite bird flu warning, FDA interstate ban

FDA approval of Sarepta Duchenne genetic therapy gives me hope

What causes osteoarthritis? Researchers study link to brain protein

Peter Hotez and the public health issue of online harassment

ALS treatment from Biogen, Ionis fails in study

explore

Inaction leaves children at risk from dangerous chemotherapy drug

Medicare bonuses could stop drug shortages under Senate plan

TikTok, Instagram influencers need more rules for drug ads

Future doctors need a strong humanities education

The United States must get value

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

focus

knowledge

hotspot

leisure time